ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CCEL / forecast
PARK (60) NIVF (20) MGRX (28) VMD (72) ⌘ Pro Terminal →

Cryo-Cell International Inc. (CCEL) 12-Month Stock Forecast & Price Target Cone

$5.35 +2.69% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.39

Cryo-Cell International Inc. (CCEL) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (steady margins, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $42.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CCEL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cryo-Cell International Inc. (NYSE: CCEL) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $5.35 (+2.69% 1D, market cap $42.0M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, CCEL ranks #79 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CCEL compare to PARK and NIVF in the Health Care sector?
▼

Within the Health Care sector (Misc Health and Biotechnology Services), CCEL carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 18.2%. By comparison, PARK (Park Dental Partners Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $100.3M) and NIVF (NewGenIvf Group Limited (Class A)) posts a E grade (20/100 RQD, P/E N/A, ROIC -32.8%, cap $9.7M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CCEL?
▼

Per CCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0000862692), Cryo-Cell International Inc. generated $1.4M in revenue (-86.1% YoY), -$2.4M in net income, and $5.2M in free cash flow against $61.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.39 (+0.72%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 388.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B-
025507510070
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk C
Cash (17)Whales (15)SEC (10)Macro (15)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
$7 Bull$6 Base$4 Bear
📬 FREE CCEL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CCEL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (70/100 Composite)
🔍 WHY CCEL SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 388.5% FCF Margin ($5.2M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (21% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk10/20 pts (-10 pt drag)

Balance-sheet & 10-K footnote risk deducts 10 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$4.30+10.5% Next Q
Q2 (-2Q)
65
Grade C+$4.75+4.4% Next Q
Q3 (-1Q)
67
Grade B-$4.96+7.9% Next Q
Current
70
Grade B-$5.35+6.6% Hist 90D α
Trajectory: C+ (62) → B- (70)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CCEL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 70/100 (B-) score, CCEL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.34) or 200D SMA ($3.70) invalidates the momentum regime and cuts Target Base ($5.64) toward Bear Floor ($4.39).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CCEL Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
YES 70%NO 30%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CCEL Position Size: $10,000

Shares at $5.35: 1869.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $4.39
$8,206
$-1,794 (-17.9%)
12M Consensus BaseTarget $5.64
$10,542
+$542 (+5.4%)
12M Bull Case BreakoutTarget $6.66
$12,449
+$2,449 (+24.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 23● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$674%A
Goldman SachsSector Coverage LeadBUY$669%B
JP MorganUS Large-Cap ResearchHOLD$558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CCEL Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +52.42%⚡ TESTING RESISTANCE
2026-11-03O $5.18H $5.35L $5.18C $5.35VOL 12.1K
RES: $5.48SUP: $3.57SMA50: $4.34SMA200: $3.70
$5.63$4.89$4.15$3.41$2.67RES $5.48SUP $3.57$5.352026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CCEL Butterfly Map → + Track CCEL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. -86.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CCEL)

Health Care Rank #79 of 1015 ⚔️ PARK vs CCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CCEL vs. PARK, NIVF, MGRX, VMD)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cryo-Cell International Inc. (CCEL) ranks #79 by composite RQD confidence (70/100, grade B-) and #765 by equity capitalization ($42.0M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. VMD currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with CCEL at 70/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CCEL ACTIVE
Cryo-Cell International Inc.
B- 70/100 — — 18.2% +2.69% $42.0M Benchmark Subject
PARK
Park Dental Partners Inc.
C- 60/100 — — — -2.09% $100.3M /park-vs-ccel →
NIVF
NewGenIvf Group Limited (Class A)
E 20/100 — — -32.8% -5.57% $9.7M /nivf-vs-ccel →
MGRX
Mangoceuticals Inc.
E 28/100 — 54.9% -35.0% -2.31% $5.2M /mgrx-vs-ccel →
VMD
Viemed Healthcare Inc.
B 72/100 24.6x 57.5% 13.0% -2.38% $368.3M /vmd-vs-ccel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-11-30 • CIK 0000862692 ↗

In its most recent audited fiscal period (FY2025, filed 2025-11-30), Cryo-Cell International Inc. (CCEL) reported GAAP revenue of $1.4M (-86.1% vs. FY2024 revenue of $9.7M , and -96.1% cumulative change since FY2023) , GAAP net income of -$2.4M, operating cash flow of $5.5M, and free cash flow of $5.2M (+45.5% YoY). On the balance sheet, CCEL closed FY2025 with $61.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-11-30 $1.4M -$2.4M $5.5M $5.2M $61.7M —
FY2024 (FY) 2024-11-30 $9.7M $402.0K $6.0M $3.6M $64.7M —
FY2023 (FY) 2023-11-30 $34.5M -$9.5M $8.9M $8.9M — —

3. CCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cryo-Cell International Inc. (NYSE: CCEL) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $5.35 (+2.69% 1D, market cap $42.0M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, CCEL ranks #79 in composite RQD confidence.

How does CCEL compare to PARK and NIVF in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), CCEL carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 18.2%. By comparison, PARK (Park Dental Partners Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $100.3M) and NIVF (NewGenIvf Group Limited (Class A)) posts a E grade (20/100 RQD, P/E N/A, ROIC -32.8%, cap $9.7M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CCEL?

Per CCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0000862692), Cryo-Cell International Inc. generated $1.4M in revenue (-86.1% YoY), -$2.4M in net income, and $5.2M in free cash flow against $61.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

CCEL last traded at $5.35 (+2.69% on volume of 12,533 shares), positioning the stock +23.27% above its 50-day simple moving average ($4.34) and +44.59% above its 200-day simple moving average ($3.70). Across its 52-week range of $2.72 to $5.45, CCEL sits at the 96.3% percentile with a 14-day RSI of 64.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.68 to $6.02).

Direct Sub-Reports: CCEL RQD Cockpit CCEL 12M Forecast CCEL Earnings & Move CCEL Dividends & DRIP CCEL Insiders & 13F CCEL Whale Options CCEL Profit Sankey CCEL News & Why
ROARABLE RATING BRIEF • RQD 70/100 (B-) ✓ SEC XBRL & RQD VERIFIED

CCEL — Cryo-Cell International Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-11-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cryo-Cell International Inc. (CCEL) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $5.35 (+2.69% 1D, market capitalization $42.0M).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 18.2%, gross margin of —, operating margin of —, and free cash flow yield of 12.55%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cryo-Cell International Inc. (CCEL) is a NYSE-listed issuer in the Health Care sector, operating in the Misc Health and Biotechnology Services industry. The profile describes it as a Health Care issuer with a market capitalization of $0.0B. — The source does not describe the company's specific products, customers, or revenue model. Revenue is reported as — in every period of the SEC financials, so the source does not establish how the business generates income.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-11-30), Cryo-Cell International Inc. (CCEL) reported $1.4M in annual revenue (up from $9.7M in FY2024, -86.1% YoY) and -$2.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($34.5M revenue, -$9.5M net income) through FY2025, CCEL scaled operating cash flow to $5.5M and free cash flow to $5.2M, backed by $61.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B- • RQD 70/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $2.72 – $5.45 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh current valuation and 61.2x EV/EBITDA against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Misc Health and Biotechnology Services (Health Care), CCEL carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can CCEL sustain or expand its — operating margin and 18.2% ROIC against Misc Health and Biotechnology Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.4M and free cash flow of $5.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CCEL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CCEL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cryo-Cell International Inc. (CCEL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CCEL Debate Forum (3) ↓
🔴 RISK WATCH Yahoo Finance • 6d ago
CCEL 8-K & SEC Filings

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9xV2xJR1VESUt1WEk4U01rN2JRQ1hNdjFBZG9JTVB4UFlkS2htMUl5RG93Z25TNUJzZkZWbXdQeGVsb3VWYjBtSXRldmR5aG1jQ2xrZ0lHZFE5azEtd3FfTXlINXhtZl9QZ3JTQlFWbkhnLVVVNmY3Yg?oc=5

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CCEL Bull vs. Bear Conversation Board — What's Your Call at $5.35?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CCEL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CCEL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $6.36 (+22.1%)
📌 Pinned Debate

CCEL (B- • RQD 70/100) operating leverage in Misc Health and Biotechnology Services is mispriced at $5.21

Picked up a starter position in CCEL in my $100K Virtual Cash book at $5.21. CCEL (B- • RQD 70/100) operating leverage in Misc Health and Biotechnology Services is mispriced at $5.21. Trading inside a $2.72–$5.45 52-week range with 12.55% FCF yield gives solid downside support if Misc Health and Biotechnology Services multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Misc Health and Biotechnology Services. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $4.48 (-14.0%)
Spot @ $5.21

The forensic balance sheet pillar scores only 10/20 with a Piotroski F of 3/9, and reported revenue is $0.0M with a 0% net margin.

Careful chasing CCEL at $5.21. The forensic balance sheet pillar scores only 10/20 with a Piotroski F of 3/9, and reported revenue is $0.0M with a 0% net margin.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $4.48 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%